Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from GlaxoSmithKline ( (GB:GSK) ) is now available.
GSK has secured expanded approval in Japan for its RSV vaccine Arexvy, which can now be used in adults aged 18-49 at increased risk of RSV disease, in addition to existing approvals in adults 50 and older, including all over 60. Japan’s updated prescribing information also explicitly recognises immunocompromised patients as an at-risk group, giving clinicians clearer guidance on which adults could benefit from vaccination.
The decision by Japan’s Ministry of Health, Labour and Welfare is backed by Phase IIIb, Phase III and Phase IIb trials showing non-inferior immune responses in younger at-risk adults and robust immunogenicity in immunocompromised transplant recipients, with a safety profile consistent with earlier studies. The move broadens GSK’s RSV footprint in a key market where many younger adults live with chronic conditions such as cardiovascular disease, COPD and asthma, and aligns with the company’s strategy to expand regulatory approvals across geographies to capture rising demand for adult RSV prevention.
The most recent analyst rating on (GB:GSK) stock is a Hold with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.
Spark’s Take on GSK Stock
According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.
The score is driven primarily by solid underlying financial performance (strong margins and improved earnings) and supportive valuation (low P/E with a ~3.47% yield). These positives are partially offset by weak technical momentum (below key moving averages with negative MACD) and financial risk factors including meaningful leverage and uneven free-cash-flow consistency.
To see Spark’s full report on GSK stock, click here.
More about GlaxoSmithKline
GSK is a global biopharmaceutical company focused on vaccines and specialty medicines, aiming to prevent and treat infectious and chronic diseases worldwide. Its portfolio includes respiratory, immunology and infectious disease products, with a growing emphasis on vaccines such as its Respiratory Syncytial Virus (RSV) shot Arexvy, which targets adult populations at heightened risk of severe illness.
Average Trading Volume: 7,819,554
Technical Sentiment Signal: Buy
Current Market Cap: £74.35B
See more insights into GSK stock on TipRanks’ Stock Analysis page.